CheckMate-649 enrolled 1581 GC patients, and first-line nivolumab plus chemotherapy resulted in significant improvements in OS (hazard ratio [HR] 0.71, P < 0.0001) and PFS (HR 0.68, P < 0.0001) versus chemotherapy alone in patients with a PD-L1 CPS of five or more; moreover, additional results showed that the OS and PFS benefits were retained in patients with CPS ≥1% (HR = 0.77, P < 0.0001; HR = 0.74, retrospectively) [57]. Here, CD274 is linked to gastric cancer.